Highlights TG Therapeutics, Inc.

Equities

TGTX

US88322Q1085

Market Closed - Nasdaq Other stock markets 01:30:00 29/06/2024 am IST			5-day change	1st Jan Change
17.79 ^USD	-0.89%		+4.77%	+4.16%

17/06	Declaration of Voting Results by TG Therapeutics	CI
17/06	Declaration of Voting Results by TG Therapeutics	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Earnings Flash (TGTX) TG THERAPEUTICS Reports Q1 Revenue $63.5M, vs. Street Est of $54.6M	01/05	MT
TG Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	01/05	CI
Sector Update: Health Care Stocks Mixed in Late Afternoon Trading	19/04	MT
Sector Update: Health Care	19/04	MT
TG Therapeutics Wins Veterans Affairs Contract for Multiple Sclerosis Drug Briumvi	18/04	MT
Tg Therapeutics, Inc. Awards National Contract by the Department of Veterans Affairs for Briumvi as the Preferred Anti-Cd20 for Relapsing Forms of Multiple Sclerosis	18/04	CI
TG Therapeutics Narrows Q4 Net Loss, Revenue Jumps; Shares Surge	28/02	MT
TG Therapeutics Narrows Q4 Net Loss, Revenue Jumps; Shares Surging in Pre-Trade	28/02	MT
Earnings Flash (TGTX) TG THERAPEUTICS Posts Q4 Revenue $44M, vs. Street Est of $40.1M	28/02	MT
TG Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28/02	CI
TG Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	28/02	CI
TG Therapeutics to Receive $12.5 Million Milestone Payment for Launch of Briumvi in Europe	26/02	MT
TG Therapeutics Acquires Worldwide License to Precision BioSciences' Allogeneic CD19 CAR T Cell Therapy Program	09/01	MT
Precision BioSciences Completes License Deal with TG Therapeutics for Cell Therapy Azer-Cel in Treatment of Autoimmune Diseases	09/01	CI
Earnings Flash (TGTX) TG THERAPEUTICS Posts Q3 Revenue $165.8M, vs. Street Est of $63.3M	01/11	MT
TG Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	01/11	CI
TG Therapeutics Signs $645 Million Sales Deal With Neuraxpharm for Briumvi	01/23/01	MT
Earnings Flash (TGTX) TG THERAPEUTICS Posts Q2 Revenue $16.1M, vs. Street Est of $17.9M	01/23/01	MT
TG Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	01/23/01	CI
TG Therapeutics, Inc. and Neuraxpharm Group Announce Ex-US Commercialization Agreement for BRIUMVI®? (ublituximab-xiiy)	01/23/01	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights TG Therapeutics, Inc.

Equities

TGTX

US88322Q1085

Highlights

Filters